FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891883713> ?p ?o ?g. }

• W2891883713 abstract "Objective: To determine whether Modified Atkins Diet (MAD), and Low-Glycemic-Index-Therapy (LGIT) diet are non-inferior to Ketogenic Diet (KD) among children with drug resistant epilepsy (DRE) Background: KD has been successfully used to treat children with DRE. However, data assessing efficacy of MAD and LGIT as compared to KD is scarce. Design/Methods: One-hundred-seventy children aged between 1 and 15 years, who had ≥4 seizures/month, had failed to respond to ≥2 anti-epileptic-drugs, and had not been treated previously with KD/MAD/LGIT participated in this trial between Apr-2016 and Aug-2017. Children were randomly assigned to receive KD, MAD or LGIT as an add-on to the ongoing antiepileptics. Primary endpoint was percentage seizure reduction from baseline at 24 weeks. The trial was powered to assess non-inferiority of MAD and LGIT compared with KD with predefined non-inferiority margin of −15%. The trial is registered with ClinicalTrials.gov, number NCT02708030. Results: One-hundred-fifty-eight children completed the trial: KD(n=52), MAD(n=52) and LGIT(n=54). After 24 weeks, in per-protocol analysis, the mean(±SD) percentage seizure reduction was −60.3(±32.8) in KD sub-group; −47.9(±45.9) in MAD sub-group; and −54.7(±40) in LGIT sub-group and the difference was statistically insignificant(p=0.18). Mean difference in seizure reduction between the KD and MAD interventions, in the per protocol analysis, was −12.33 (95%CI= −25.16, 0.50); and between KD and LGIT interventions was −5.66 (95%CI= −17.34, 6.02). Adverse events (AE) were noted in 83/170(48.9%) patients; most commonly vomiting (42.4%), diarrhoea (14.5%), constipation (36.5%) and decreased satiety (15.9%). LGIT intervention had significantly lesser AE than KD and MAD interventions(p=0.036). Serious AE were observed in 12/170 (7.1%) patients: metabolic acidosis (pH Conclusions: MAD and LGIT were not non-inferior to KD. Nonetheless, patients on LGIT demonstrated >50% seizure reduction with a better safety profile. Disclosure: Dr. Sondhi has nothing to disclose. Dr. Agarwala has nothing to disclose. Dr. Chakrabarty has nothing to disclose. Dr. Jauhari has nothing to disclose. Dr. Lodha has nothing to disclose. Dr. Pandey has nothing to disclose. Dr. Toteja has nothing to disclose. Dr. Paul has nothing to disclose. Dr. Gulati has nothing to disclose." @default.
• W2891883713 created "2018-09-27" @default.
• W2891883713 creator A5011155969 @default.
• W2891883713 creator A5026153129 @default.
• W2891883713 creator A5030097128 @default.
• W2891883713 creator A5035530253 @default.
• W2891883713 creator A5038826897 @default.
• W2891883713 creator A5039572099 @default.
• W2891883713 creator A5060669389 @default.
• W2891883713 creator A5070687190 @default.
• W2891883713 creator A5078578928 @default.
• W2891883713 date "2018-04-10" @default.
• W2891883713 modified "2023-09-27" @default.
• W2891883713 title "Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non-Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy (S35.006)" @default.
• W2891883713 hasPublicationYear "2018" @default.
• W2891883713 type Work @default.
• W2891883713 sameAs 2891883713 @default.
• W2891883713 citedByCount "0" @default.
• W2891883713 crossrefType "journal-article" @default.
• W2891883713 hasAuthorship W2891883713A5011155969 @default.
• W2891883713 hasAuthorship W2891883713A5026153129 @default.
• W2891883713 hasAuthorship W2891883713A5030097128 @default.
• W2891883713 hasAuthorship W2891883713A5035530253 @default.
• W2891883713 hasAuthorship W2891883713A5038826897 @default.
• W2891883713 hasAuthorship W2891883713A5039572099 @default.
• W2891883713 hasAuthorship W2891883713A5060669389 @default.
• W2891883713 hasAuthorship W2891883713A5070687190 @default.
• W2891883713 hasAuthorship W2891883713A5078578928 @default.
• W2891883713 hasConcept C118552586 @default.
• W2891883713 hasConcept C126322002 @default.
• W2891883713 hasConcept C168563851 @default.
• W2891883713 hasConcept C187212893 @default.
• W2891883713 hasConcept C202953159 @default.
• W2891883713 hasConcept C203092338 @default.
• W2891883713 hasConcept C2778186239 @default.
• W2891883713 hasConcept C2778587478 @default.
• W2891883713 hasConcept C2910833928 @default.
• W2891883713 hasConcept C535046627 @default.
• W2891883713 hasConcept C71924100 @default.
• W2891883713 hasConceptScore W2891883713C118552586 @default.
• W2891883713 hasConceptScore W2891883713C126322002 @default.
• W2891883713 hasConceptScore W2891883713C168563851 @default.
• W2891883713 hasConceptScore W2891883713C187212893 @default.
• W2891883713 hasConceptScore W2891883713C202953159 @default.
• W2891883713 hasConceptScore W2891883713C203092338 @default.
• W2891883713 hasConceptScore W2891883713C2778186239 @default.
• W2891883713 hasConceptScore W2891883713C2778587478 @default.
• W2891883713 hasConceptScore W2891883713C2910833928 @default.
• W2891883713 hasConceptScore W2891883713C535046627 @default.
• W2891883713 hasConceptScore W2891883713C71924100 @default.
• W2891883713 hasLocation W28918837131 @default.
• W2891883713 hasOpenAccess W2891883713 @default.
• W2891883713 hasPrimaryLocation W28918837131 @default.
• W2891883713 hasVolume "90" @default.
• W2891883713 isParatext "false" @default.
• W2891883713 isRetracted "false" @default.
• W2891883713 magId "2891883713" @default.
• W2891883713 workType "article" @default.